Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA warns about non-GRAS cold products

This article was originally published in The Tan Sheet

Executive Summary

Boca Pharmacal markets OTCs containing prescription ingredients, making them products not generally recognized as safe and effective for use. In in a July 22 warning letter to the Coral Spring, Fla-based firm, FDA says the labels of the products - Pseudo DM GG Syrup and C-Phen DM Drops - suggest they diagnose, cure, mitigate, treat or prevent disease, although the drugs do not have approved applications. The agency adds the drugs are mislabeled for consumer use because the Rx ingredients are indicated for conditions that are not "amenable to self-diagnosis and treatment of individuals who are not medical practitioners." Boca, which contracted another firm to manufacture the products, has 15 days from receipt of the warning to notify FDA of its work to correct the violations and prevent a recurrence. The warning letter posted Sept. 20 on FDA's website does not identify the contract manufacturer

You may also be interested in...



Without US CBD Guidance, Low-Quality Supplements, State Rules Hurt Industry

“Responsible” CBD supplement marketers are disadvantaged against “bad actors” with products taking up shelf space in “disloyal” retailers as federal regulatory limbo drags on, says nutritional science expert Duffy McKay. Patchwork of state regulations on CBD also create challenges.

Shiseido Aims To Be World’s No. 1 ‘Skin Beauty’ Company By 2030

With makeup and lipstick sales down globally at a time of wide mask use, Shiseido is focused on skin health, planning launches to address sensitive skin needs and heightened demand for cleansing and protection effects. In August, the firm projected a 16% decline in net sales for full-year fiscal 2020.

EU Firsts Beckon For Olumiant In Dermatitis & Orfadin For AKU

The European Medicine Agency has recommended extending the therapeutic indication of a raft of drugs that are already authorized in the EU.

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel